Group One Trading, L.P. Inmune Bio, Inc. Transaction History

Group One Trading, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$6.6 - $11.52 $287,852 - $502,433	-43,614 Reduced 94.84%	2,375 $26,000
Q3 2023 Nov 09, 2023	BUY	$6.61 - $10.9 $154,350 - $254,525	23,351 Added 103.15%	45,989 $311,000
Q2 2023 Aug 09, 2023	BUY	$6.5 - $10.09 $88,413 - $137,244	13,602 Added 150.53%	22,638 $205,000
Q1 2023 May 12, 2023	BUY	$6.01 - $10.18 $46,421 - $78,630	7,724 Added 588.72%	9,036 $58,000
Q4 2022 Feb 09, 2023	SELL	$6.31 - $7.96 $219,865 - $277,358	-34,844 Reduced 96.37%	1,312 $8,000

Q3 2022 Nov 09, 2022	BUY	$6.91 - $10.44 $18,539 - $28,010	2,683 Added 8.02%	36,156 $224,000
Q2 2022 Aug 11, 2022	BUY	$5.48 - $8.97 $52,164 - $85,385	9,519 Added 39.74%	33,473 $296,000
Q1 2022 May 12, 2022	SELL	$6.42 - $11.39 $44,124 - $78,283	-6,873 Reduced 22.3%	23,954 $202,000
Q4 2021 Feb 11, 2022	BUY	$9.97 - $20.38 $129,819 - $265,367	13,021 Added 73.13%	30,827 $314,000
Q3 2021 Nov 12, 2021	BUY	$14.13 - $27.85 $185,526 - $365,670	13,130 Added 280.8%	17,806 $346,000
Q2 2021 Aug 10, 2021	BUY	$9.29 - $19.33 $43,440 - $90,387	4,676 New	4,676 $82,000

2.88M

44.6K

3.5K

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $145M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.